Akari Therapeutics (AKTX) Restructuring Costs (2024)

Akari Therapeutics (AKTX) reported Restructuring Costs of $983000.0 for Q4 2024, down 0.91% sequentially from $992000.0 in Q3 2024.

Akari Therapeutics (AKTX) Restructuring Costs (2024) Analysis & Trends

Akari Therapeutics (AKTX) has 1 years of Restructuring Costs data on file, last reported at $983000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Alnylam Pharmaceuticals	36.08 Bn	33.07 Bn	959.66 Mn

Download Data